Exposure to high-fat diet since post-weaning induces cardiometabolic damage in adult rats

Imagem de Miniatura
Arquivos
art_FIORINO_Exposure_to_highfat_diet_since_postweaning_induces_cardiometabolic_2016.PDF (315.33 KB)
Citações na Scopus
12
Tipo de produção
article
Data de publicação
2016
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
PERGAMON-ELSEVIER SCIENCE LTD
Autores
FIORINO, P.
EVANGELISTA, F. S.
LEITE, A. P. O.
FARAH, V.
Citação
LIFE SCIENCES, v.160, p.12-17, 2016
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Aims: This study sought to investigate the metabolic, hemodynamic and autonomic responses in adult rats exposed to high-fat diet since post-weaning. Main methods: Young male Wistar rats were assigned into groups fed with standard normal diet (3% lipids; ND, n=8) or high-fat diet (30% lipids; HD, n=8) during 8 weeks. Body composition, food intake, serum triglycerides, total cholesterol, insulin, leptin and adiponectin concentrations were determined. Hemodynamic and autonomic evaluations were performed. Renin angiotensin system and nitric oxide were also studied by pharmacological blockades. Key findings: HD group showed no difference in body weight, total cholesterol, food intake in calories and insulin concentration, but visceral fat pads weight, triglycerides and leptin were higher in HD group. Moreover, HD group decreased adiponectin level, increased 12% of mean arterial pressure (MAP) and 6% of heart rate compared with ND group. Spectral analyses showed an increase in cardiovascular sympathetic modulation in HD compared with ND group. Depressor responses after losartan were higher in HD compared with ND group: -9 +/- 0.7 vs.-3 +/- 1.6 mmHg. Pressor responses after L-NAME were higher in HD compared with ND: 45 +/- 8 vs. 32 +/- 5 mmHg. Significance: High-fat diet consumption during early period of life can increase WAT mass and MAP. These alterations may be mediated by an augment in sympathetic activity associated with higher leptin and lower adiponectin levels. These cardiometabolic damages can lead to the development of hypertension and increase cardiovascular risk in adulthood.
Palavras-chave
Obesity, Arterial pressure, Autonomic dysfunction, Adipokines, High-fat diet
URI
https://observatorio.fm.usp.br/handle/OPI/17196
Referências
  1. Aghamohammadzadeh R, 2012, ANN MED, V44, pS74, DOI 10.3109/07853890.2012.663928
  2. De Angelis K., 1999, HYPERTENSION, V34, P768
  3. Araujo IC, 2016, EUR J NUTR, V55, P83, DOI 10.1007/s00394-014-0826-5
  4. Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255
  5. Assadi F, 2012, PEDIATR CARDIOL, V33, P1013, DOI 10.1007/s00246-012-0333-5
  6. Bruno RM, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00284
  7. Celoria B.M.J., 2010, CLIN CARDIOL, V33, P61
  8. Chantemele E.J.B., 2011, HYPERTENSION, V58, P271
  9. Dake BL, 2015, OBESITY, V23, P623, DOI 10.1002/oby.21009
  10. De Angelis K, 2012, AM J PHYSIOL-REG I, V302, pR950, DOI 10.1152/ajpregu.00450.2011
  11. DeMarco VG, 2014, NAT REV ENDOCRINOL, V10, P364, DOI 10.1038/nrendo.2014.44
  12. Diniz YS, 2006, EUR J PHARMACOL, V543, P151, DOI 10.1016/j.ejphar.2006.05.039
  13. Dunbar JC, 1997, DIABETES, V46, P2040, DOI 10.2337/diabetes.46.12.2040
  14. Fonseca-alaniz M.H., 2006, ARQ BRAS ENDOCRINOL, V50
  15. Fruhbeck G, 1999, DIABETES, V48, P903, DOI 10.2337/diabetes.48.4.903
  16. Fyhrquist F, 2008, J INTERN MED, V264, P224, DOI 10.1111/j.1365-2796.2008.01981.x
  17. Hall JE, 2015, CIRC RES, V116, P991, DOI 10.1161/CIRCRESAHA.116.305697
  18. Haynes WG, 2005, EXP PHYSIOL, V90, P683, DOI 10.1113/expphysiol.2005.031237
  19. Haynes WG, 1997, J CLIN INVEST, V100, P270, DOI 10.1172/JCI119532
  20. Higa TS, 2014, LIFE SCI, V103, P41, DOI 10.1016/j.lfs.2014.02.039
  21. Higa Talita S, 2014, Int J Physiol Pathophysiol Pharmacol, V6, P47
  22. Jackman MR, 2010, AM J PHYSIOL-REG I, V299, pR1097, DOI 10.1152/ajpregu.00549.2009
  23. Kalil GZ, 2012, HYPERTENS RES, V35, P4, DOI 10.1038/hr.2011.173
  24. Kim DH, 2013, HYPERTENSION, V62, P27, DOI 10.1161/HYPERTENSIONAHA.113.01453
  25. Kloet A.D., 2010, PHYSIOL BEHAV, V100, P525
  26. La Rovere MT, 2009, J AM COLL CARDIOL, V53, P193, DOI 10.1016/j.jacc.2008.09.034
  27. Marcus Y, 2013, MOL CELL ENDOCRINOL, V378, P1, DOI 10.1016/j.mce.2012.06.021
  28. Marsh AJ, 2003, HYPERTENSION, V42, P488, DOI 10.1161/01.HYP.0000090097.22678.0A
  29. Matsuda K, 2003, HYPERTENS RES, V26, P147, DOI 10.1291/hypres.26.147
  30. Muntzel MS, 2012, HYPERTENSION, V60, P1498, DOI 10.1161/HYPERTENSIONAHA.112.194886
  31. Nascimento AF, 2008, BIOL RES, V41, P253, DOI [/S0716-97602008000300002, 10.4067/S0716-97602008000300002]
  32. Pan HT, 2014, PHYSIOL BEHAV, V130, P157, DOI 10.1016/j.physbeh.2014.04.003
  33. Papadopoulos Dimitrios P, 2005, J Clin Hypertens (Greenwich), V7, P729, DOI 10.1111/j.1524-6175.2005.04888.x
  34. Qi GM, 2014, ENDOCRINOLOGY, V155, P2254, DOI 10.1210/en.2013-2011
  35. Rahmouni K, 2004, RECENT PROG HORM RES, V59, P225, DOI 10.1210/rp.59.1.225
  36. Rahmouni K, 2005, DIABETES, V54, P2012, DOI 10.2337/diabetes.54.7.2012
  37. Rajkovic N, 2014, INT J ENV RES PUB HE, V11, P4049, DOI 10.3390/ijerph110404049
  38. Riley M, 2012, AM FAM PHYSICIAN, V85, P693
  39. Rojas E, 2014, CURR HYPERTENS REP, V16, DOI 10.1007/s11906-014-0463-7
  40. Strazzullo P, 2003, ANN INTERN MED, V138, P17
  41. Surwit RS, 1998, P NATL ACAD SCI USA, V95, P4061, DOI 10.1073/pnas.95.7.4061
  42. Takahashi N, 2007, METABOLISM, V56, P919, DOI 10.1016/j.metabol.2007.02.005
  43. Tanida M, 2007, EXP BIOL MED, V232, P390
  44. WHO, 2014, OB OV
  45. Woods SC, 2003, J NUTR, V133, P1081
  46. Wu XD, 2003, DIABETES, V52, P1355, DOI 10.2337/diabetes.52.6.1355
  47. Yoon MJ, 2006, DIABETES, V55, P2562, DOI 10.2337/db05-1322

Coleções
Artigos e Materiais de Revistas Científicas - FM/Outros
Artigos e Materiais de Revistas Científicas - LIM/59
Artigos e Materiais de Revistas Científicas - ODS/03